Quarterly ResultNov 5, 2026, 06:21 AM
Cognition Therapeutics Reports Q3 2026 Net Loss of $4.15M
AI Summary
Cognition Therapeutics Inc. (CGTX) filed its Form 10-Q for the period ending September 30, 2026. The company reported a net loss of $4.15 million for the third quarter of 2026, an improvement from a net loss of $4.93 million in the same period of 2025. For the nine-month period, the net loss was $12.65 million, down from $20.14 million in 2025. While research and development expenses increased year-over-year for the quarter, total operating expenses also rose. The company's cash position decreased to $30.76 million from $36.81 million at the end of 2025, but management believes it is sufficient to fund operations for the next year.
Key Highlights
- Cognition Therapeutics reported a net loss of $4.15 million for Q3 2026, compared to $4.93 million in Q3 2025.
- For the nine months ended September 30, 2026, the net loss was $12.65 million, a decrease from $20.14 million in the same period of 2025.
- Research and development expenses decreased to $5.12 million in Q3 2026 from $3.77 million in Q3 2025.
- Total operating expenses for Q3 2026 were $7.38 million, up from $6.38 million in Q3 2025.
- Cash and cash equivalents stood at $30.76 million as of September 30, 2026, down from $36.81 million as of December 31, 2025.
- The company has sufficient cash to fund operations for one year from the filing date.
- Grant income for Q3 2026 was $2.97 million, an increase from $1.22 million in Q3 2025.
Price Impact
More from CGTX